Company research
NERVGEN PHARMA CORP.
CIK 1751912Updated Nov 19, 2026
NGEN price & chart
Loading TradingView…
NASDAQ:NGEN on TradingView ↗About the company
NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide designed to counteract the inhibitory effects of chondroitin sulfate proteoglycans. NVG-291 has received Breakthrough Therapy designation from the FDA for the treatment of chronic traumatic cervical motor-incomplete SCI, based on preliminary clinical evidence from the Phase 1b/2a CONNECT SCI study indicating the potential for substantial improvement over available therapy on one or more clinically significant endpoints. NVG-291 has also received FDA Fast Track designation and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
In the news
NervGen to Host Inaugural R&D Day on September 30, 2026 ↗
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer ↗
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · CADSource
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossCAD | -44,117,305Source | -24,250,049Source |
| Additional Financial Items | ||
| AdjustmentsForSharebasedPaymentsCAD | 5,394,914Source | 6,039,724Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | -452,134Source | 294,337Source |
| GeneralAndAdministrativeExpenseCAD | 11,172,046Source | 9,365,129Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD | 100,926Source | 100,926Source |
| ProceedsFromIssuingSharesCAD | 16,884,659Source | 23,011,788Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Additional Financial Items | ||
| BasicEarningsLossPerShareCAD/shares | -0.61Source | -0.36Source |
| DepreciationRightofuseAssetsCAD | — | 22,490Source |
| DilutedEarningsLossPerShareCAD/shares | -0.61Source | -0.36Source |
| FinanceIncomeCAD | 333,415Source | 812,617Source |
| GeneralAndAdministrativeExpenseCAD | 11,172,046Source | 9,365,129Source |
| InterestExpenseOnLeaseLiabilitiesCAD | 3,691Source | 9,340Source |
| ResearchAndDevelopmentExpenseCAD | 13,907,206Source | 15,811,020Source |
Filing attachments
tm2630103d1_ex99-1.htm · 6-K · 2026-11-18
Exhibit 99.1 NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer Dr. Jackson brings expertise in innovative neuroscience trial design, leading pivotal Phase 3 studies and supporting FDA approval He will lead execution of the ongoing Phase 3 RESTORE study and support clinical expansion of NVG-291 as a potential pipeline-in-a-product MIAMI - November 18, 2026 - NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company devel…
Read attachment ↗tm2629739d1_ex99-1.htm · 6-K · 2026-11-16
Exhibit 99.1 Condensed consolidated interim financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars - Unaudited) For the three months and nine months ended September 30, 2026 and 2025 NERVGEN PHARMA CORP. Condensed Consolidated Interim Statements of Financial Position (Expressed in Canadian dollars) (Unaudited) as at September 30, 2026 December 31, 2025 Assets Current ass…
Read attachment ↗tm2629739d1_ex99-2.htm · 6-K · 2026-11-16
Exhibit 99.2 Management’s Discussion and Analysis of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the three and nine months ended September 30, 2026 and 2025 Effective Date: November 16, 2026 MANAGEMENT’S DISCUSSION AND ANALYSIS The following discussion is management’s assessment and analysis of the results of operations and financial condition of NervGen Pharma Corp. (the “Company” or “NervGen”) and should be read in conjunction with the accompanying condensed consolidated in…
Read attachment ↗tm2627645d1_ex99-1.htm · 6-K/A · 2026-10-16
Exhibit 99.1 Amended and Restated Condensed consolidated interim financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars - Unaudited) For the three months and six months ended June 30, 2026 and 2025 NERVGEN PHARMA CORP. Condensed Consolidated Interim Statements of Financial Position (Expressed in Canadian dollars) (Unaudited) as at June 30, December 31, …
Read attachment ↗tm2627645d1_ex99-2.htm · 6-K/A · 2026-10-16
Exhibit 99.2 Amended and Restated Management’s Discussion and Analysis of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the three and six months ended June 30, 2026 and 2025 Effective Date: October 16, 2026 MANAGEMENT’S DISCUSSION AND ANALYSIS The following discussion is management’s assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. (the “Company” or “NervGen”) and should be read in conjunction with the accompanying condensed …
Read attachment ↗ngen-20251231xex99d2.htm · 40-F/A · 2026-10-16
Exhibit 99.2 Amended and Restated Consolidated financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the years ended December 31, 2025 and 2024 Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors NervGen Pharma Corp.: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated statements of financial position of NervGen Pharma Corp. (the Company) as of December 31, 2025 and 2024,…
Read attachment ↗